Acute Coronary Syndrome

Leeper, Barbara; Cyr, Alaina; Lambert, Christa; Martin, Kimberlee

doi:10.1016/j.ccell.2011.10.001

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На всем протяжении наблюдения у больных ОКС независимо от наличия или отсутствия сопутствующих нарушений аффективного спектра выявляется высокий уровень маркера эндотелиального повреждения -ФВ. Установлено, что у пациентов с сердечно-сосудистыми заболеваниями возрастает тромбогенность сосудистой стенки, чему способствует повышение содержания ФВ [1,2]. Однако в группе пациентов, получавших лечение вальдоксаном, значения ФВ на 10-й день наблюдения ниже, чем у пациентов, не получавших антидепрессант.…”

Section: Discussionunclassified

“…стабильная стенокардия и/или ИМ без подъема сегмента на ЭКГ составляют около 80% от всего числа ОКС. Оставшиеся 20% приходятся на долю ИМ с подъемом сегмента ST на ЭКГ, и приблизительно треть из этих больных умирают в течение первых 24 ч от появления ишемии миокарда [1]. Причиной подавляющего большинства случаев ОКС является атеросклероз, характеризующийся эндотелиальной дисфункцией, гиперплазией интимы, воспалением, пролиферацией гладкомышечных волокон и отложением липидов в сосудистой стенке с образованием атеросклеротической бляшки.…”

unclassified

See 1 more Smart Citation

An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders

Shimohina

Петрова

Савченко

et al. 2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

unclassified

An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders

Shimohina

Петрова

Савченко

et al. 2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

show abstract

“…In acute MI cases, especially in ST-segment elevation MI (STEMI), it is important to applies pharmacological reperfusion therapy administration as soon as possible, either by percutaneous coronary intervention (PCI) or fibrinolytic medications, to reduce morbidity and mortality rates. 4,16,17 Patients with non-STsegment elevation MI (NSTEMI) or unstable angina pectoris (UAP) are also in indication for early catheterization, in addition to an intensive antiplatelet therapy. Revascularization of unstable coronary lesion is important to prevent future ischemic complications.…”

Section: Copeptin As a Myocardial Infarction Biomarkermentioning

confidence: 99%

The role of copeptin as a novel cardiovascular biomarker

Kristyagita

Siswanto

2015

Med J Indones

View full text Add to dashboard Cite

Copeptin is a provasopressin-derived peptide, the precursor for arginine vasopressin (AVP), which is an antidiuretic hormone from the hypothalamus. Copeptin is secreted together with AVP equally as a response of AVP stimulation. While AVP’s main function is water and blood volume regulation and maintaining electrolyte homeostasis, copeptin’s function is still not fully understood. AVP, copeptin, and other vasopressinergic neuropeptides’ levels are elevated in acute stress caused by pathological conditions. Clinical use of AVP levels has many weaknesses. Copeptin can act as a replacement because of its molecular stability, easier testing methods, and faster results. For example, combination of copeptin and cardiac troponins can eliminate myocardial infarction (MI) diagnosis faster, while combined with brain-type natriuretic peptide (BNP) or its precursor can predict heart failure (HF) outcome. In cardiovascular shock, copeptin levels are elevated. As such, copeptin is a potential biomarker for MI diagnosis and predictor for HF mortality and morbidity.

show abstract

“…Acute coronary syndrome (ACS) represents a spectrum of processes that occur as atherosclerosis progresses. These include unstable angina, non ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), which are associated with an increased risk of cardiac death (Leeper, Cyr, Lambert, & Martin, 2011). These life-threatening illnesses are a significant health concern in Canada, are major contributors to emergency department use and hospitalizations, and have a negative effect on people's quality of life, including income.…”

Section: Chapter One: Introductionmentioning

confidence: 99%

Ethnicity-based Differences in Treatment-seeking for Symptoms of Acute Coronary Syndrome

Iacoe

Ratner

Wong

et al. 2016

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Background: Patient-related delays in acquiring medical care for symptoms of acute coronary syndrome (ACS) remain unacceptably long despite campaigns aimed at raising awareness of the importance of timely presentation to an urgent care facility. Patients who delay seeking treatment for ACS often experience delays in treatment initiation, which can lead to poorer outcomes. Many sociodemographic characteristics associated with treatment-seeking delay are known, however ethnicity and how it relates to delay, have not been extensively evaluated. Objective: The purpose of this study was to explore ethnicity-based factors to determine how they relate to the treatment-seeking decisions of patients experiencing symptoms of ACS. Method: Data for this descriptive study were collected for the Acute Coronary Syndrome Care in Emergency Departments ("ASCEND") study. The ASCEND study is a prospective, observational study in which patients presenting to hospital emergency departments and triaged as having symptoms suggestive of ACS are identified. The primary outcome of this study, the patients' time-to-treatment interval, was defined as the time between the occurrences of symptom onset and appropriate treatment seeking. The predictor variable, ethnicity, was measured with the self-reported data and categorized as Chinese, South Asian, or "Other" ethnic groups. Univariate and multivariate analyses were used along with nonparametric testing. Results: The study sample consisted of 401 participants; 30 Chinese, 102 South Asian, and 269 participants who were characterized as "Other". The median time-to-treatment-seeking interval, for the total sample, was 180 minutes (IQR = 1,170 minutes). A Kruskal-Wallis test iii demonstrated no statistically significant differences in the time-to-treatment intervals by ethnicity; however, the sample may not have provided sufficient statistical power to detect a difference. No ethnic differences were found in the participants' reasons for employing the coping strategies or actions that led to their treatment-seeking delay. A statistically significant relationship was found between ethnicity and the actions taken by the participants in response to their symptoms of ACS. The South Asian participants were most likely to call for the help of a family member, co-worker or stranger nearby, or telephoned a family member, which likely prolonged the time it took to obtain medical care. iv Preface This thesis is based on data from the Acute Coronary Syndrome Care in Emergency Departments ("ASCEND") study, a prospective, observational study (Dr. Martha Mackay is the principal investigator). None of the text of the thesis is taken from previously published manuscripts. The study was approved by the University of British Columbia, Providence Health Care Research Ethics Boards (REB) (certificate UBC-PHC #H13-00617).

show abstract

Acute Coronary Syndrome

Cited by 6 publications

References 22 publications

An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders

An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders

The role of copeptin as a novel cardiovascular biomarker

Ethnicity-based Differences in Treatment-seeking for Symptoms of Acute Coronary Syndrome

Contact Info

Product

Resources

About